Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Boost for Post-CAR-T Myelosuppression in B-NHL
NCT06589089Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous hematopoietic stem cells in myelosuppression, sponsored by Ruijin Hospital. Started Oct 2024; status: recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06589089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589089.